PEG-Epo50 mcg/0.3 ml

PEG-Epo is a long-acting erythropoiesis-stimulating agent (ESA) indicated for:

• Established/FDA-approved use: Treatment of anemia associated with chronic kidney disease (CKD) in adult patients, including patients on dialysis and patients not on dialysis.

Not indicated for:

• Anemia due to cancer chemotherapy (not an approved indication for this agent).
• Use as a substitute for red blood cell (RBC) transfusion in patients requiring immediate correction of anemia.
• Anemia from causes other than CKD (e.g., iron deficiency, chronic disease unrelated to renal failure) unless specifically directed by a physician after excluding other causes.

Because of its long half-life, PEG-Epo allows for less frequent dosing (once every 2 or 4 weeks) compared with shorter-acting erythropoiesis-stimulating agents.

Each vial/pre-filled syringe contains Pegylated Erythropoietin (methoxy polyethylene glycol-epoetin beta) as the active ingredient, supplied as a sterile solution for injection in strengths intended for individualized, weight-based or fixed dosing as determined by the prescribing physician.

PEG-Epo is a continuous erythropoietin receptor activator (CERA), a pegylated derivative of recombinant human erythropoietin. Pegylation (attachment of a large polyethylene glycol polymer to the erythropoietin molecule) prolongs the drug's circulating half-life, allowing for extended dosing intervals compared to conventional epoetins.

PEG-Epo works by stimulating erythropoiesis (red blood cell production) in the bone marrow, in the same manner as endogenous erythropoietin, and is used specifically to manage anemia associated with chronic kidney disease.

PEG-Epo belongs to the therapeutic class of Erythropoiesis-Stimulating Agents (ESAs), specifically classified as a continuous erythropoietin receptor activator (CERA).

Pegylated Erythropoietin acts on the erythropoietin receptor on erythroid progenitor cells in the bone marrow, stimulating their proliferation and differentiation into mature red blood cells, thereby increasing hemoglobin and hematocrit levels.

The pegylation of Pegylated Erythropoietin increases its molecular size and reduces its clearance, resulting in a substantially prolonged elimination half-life (approximately 130 hours after intravenous or subcutaneous administration) compared to non-pegylated erythropoietin products. This pharmacokinetic profile permits maintenance dosing as infrequently as once monthly in stable patients.

Onset of the erythropoietic response is gradual, typically requiring several weeks of therapy before a meaningful rise in hemoglobin is observed, consistent with the natural time course of red blood cell maturation.

PEG-Epo is administered by intravenous (IV) injection or subcutaneous (SC) injection, as a pre-filled syringe or vial for single use. Hemodialysis patients typically receive it intravenously at the end of a dialysis session; non-dialysis patients typically receive it subcutaneously.

• Do not shake the syringe/vial vigorously; vigorous shaking may denature the protein.
• Inspect visually for particulate matter and discoloration before use; discard if present.
• Each syringe/vial is for single use only; discard unused portion.
• Do not dilute or administer with other drug solutions.

No formal, clinically significant pharmacokinetic drug-drug interaction studies have identified major interactions for PEG-Epo. Relevant considerations include:

• Iron supplements: Adequate iron stores are required for an effective erythropoietic response to PEG-Epo; supplemental iron is often needed and should be optimized before and during therapy (see Precautions).
• Other erythropoiesis-stimulating agents: Concomitant use of PEG-Epo with other ESAs is not recommended, as it does not provide additional efficacy benefit and may increase risk.
• Drugs affecting blood pressure: Because PEG-Epo can increase blood pressure, concurrent antihypertensive therapy may require dose adjustment (see Precautions and Warnings).

Common side effects reported with PEG-Epo include:

• Hypertension
• Diarrhea
• Nasopharyngitis / upper respiratory tract infection
• Headache
• Injection site reactions
• Peripheral edema

Serious side effects (see Precautions and Warnings for full discussion): increased risk of death, myocardial infarction, stroke, and venous thromboembolism when hemoglobin is targeted above recommended levels; vascular access thrombosis in dialysis patients; pure red cell aplasia (rare); severe hypersensitivity/anaphylactic reactions; seizures, particularly in the early weeks of therapy in CKD patients.

There are no adequate and well-controlled studies of PEG-Epo use in pregnant women. PEG-Epo should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; consult a physician before use in pregnancy.

It is not known whether PEG-Epo is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised and a physician consulted when PEG-Epo is administered to a breastfeeding woman.

Boxed Warning (ESA Class)

Erythropoiesis-stimulating agents, including PEG-Epo, increase the risk of death, myocardial infarction, stroke, venous thromboembolism, and tumor progression or recurrence when used to target hemoglobin levels higher than recommended, and in certain cancer patients not receiving concurrent chemotherapy. PEG-Epo is not approved for use in cancer-related anemia. The lowest dose sufficient to reduce the need for RBC transfusion should be used, and dosing must be individualized.

Cardiovascular Risk

Excessive or rapid rise in hemoglobin increases cardiovascular and thromboembolic risk. Hemoglobin should be monitored regularly, and the dose adjusted to avoid exceeding recommended target hemoglobin thresholds.

Hypertension

Blood pressure should be adequately controlled prior to initiation and monitored regularly during treatment with PEG-Epo; uncontrolled hypertension is a contraindication (see Contraindications).

Thromboembolic Events

Thromboembolic risk is particularly relevant in cancer patients and in pre-surgical settings; use with caution and appropriate monitoring in these situations.

Iron Status

Iron status (including transferrin saturation and ferritin) should be evaluated in all patients before and periodically during treatment; adequate iron supplementation should be ensured, as iron deficiency reduces the response to PEG-Epo.

Seizures

Seizures have been reported with the ESA class; monitor closely, especially during the early months of treatment, in patients with CKD.

Pure Red Cell Aplasia

Discontinue PEG-Epo permanently in patients who develop antibody-mediated PRCA; do not switch to another ESA (see Contraindications).

Overdose of PEG-Epo may result in an excessive erythropoietic response, leading to polycythemia (hemoglobin/hematocrit above the desired range), which can increase the risk of serious cardiovascular and thromboembolic complications.

There is no specific antidote. In case of suspected overdose, seek immediate medical attention or contact emergency services/poison control. Management is supportive and may include withholding PEG-Epo, close monitoring of hemoglobin/hematocrit, and phlebotomy if clinically indicated, as directed by a physician.

Store in a refrigerator (2°C to 8°C / 36°F to 46°F). Do not freeze. Keep the pre-filled syringe/vial in the outer carton to protect from light. Do not shake. Keep out of reach of children.

Renal impairment: PEG-Epo is specifically indicated for anemia associated with chronic kidney disease; dosing is individualized based on hemoglobin response and dialysis status (see Dosage and Administration).

Hepatic impairment: No specific dose adjustment has been well established; use with routine clinical monitoring.

Elderly: No overall differences in safety or effectiveness have been observed between elderly and younger adult patients, but cardiovascular risk factors are often more prevalent and should be monitored closely.

Pediatric use: Safety and efficacy of PEG-Epo have not been established in pediatric patients (see Pediatric Uses).

Pregnancy/lactation: See Pregnancy and Lactation section.

Duration of treatment with PEG-Epo is individualized and typically long-term/ongoing for as long as the underlying chronic kidney disease and associated anemia persist, with periodic reassessment of hemoglobin, iron status, blood pressure, and continued need by the treating physician.

Erythropoiesis-Stimulating Agent (ESA); Continuous Erythropoietin Receptor Activator (CERA)

Pegylated Erythropoietin binds to and activates the erythropoietin receptor on erythroid progenitor cells in the bone marrow, stimulating their division and differentiation into mature erythrocytes, thereby increasing red blood cell production. Pegylation prolongs receptor activation and systemic exposure, allowing for sustained erythropoietic stimulation with less frequent dosing.

C

The safety and efficacy of PEG-Epo have not been established in pediatric patients. Use in children should only be considered under specialist supervision when no suitable alternative exists, with close monitoring of hemoglobin, blood pressure, and iron status.